The dispute with pharmaceutical firms over the use of contract pharmacies for 340B covered entities is the biggest crisis facing the program since its inception in the early 1990s, 340B Report Publisher and CEO Ted Slafsky tells “The Future of Pharmacy” podcast.
In an approximately 20-minute discussion with Ken Perez, Vice President, Healthcare Policy and Government Affairs, of pharmacy automation company Omnicell
The dispute with pharmaceutical firms over the use of contract pharmacies for 340B covered entities is the biggest crisis facing the program since its inception in the early 1990s, 340B Report CEO and Publisher Ted Slafsky tells “The Future of Pharmacy” podcast.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
